In its seventh year, the annual culinary event Dim Sum Give Some in Milwaukee will host a record number of all-star chefs ...

Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced multiple abstracts selected for ...

The lipid nanoparticles market growth is driven by rising demand for advanced drug delivery systems, increasing adoption of ...

AnnJi Pharmaceutical Co., Ltd. (AnnJi, TWSE: 7754) announced its participation in the 2026 International Patient and ...

REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2025.

Late-stage gene therapy pipeline for rare and retinal diseases advancing toward key catalysts RGX-202 for Duchenne muscular dystrophy: New Phase I/II data at ...

Decades of research on prevention methods is available, but parents, researchers and trainers say that teams, coaches and ...

With nearly 100,000 tech workers in the Austin metro, the Pecan Park studio treats chronic neck, shoulder, and back ...

AnnJi Pharmaceutical Co., Ltd. (AnnJi, TWSE: 7754) announced its participation in the 2026 International Patient and Scientific Conference hosted by the ...

A pre-clinical biopharmaceutical company dedicated to precision cardiology through targeted RNA therapeutics designed to ...

Commercially launched in the U.S. in November 2025, TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime is the first new FDA-approved treatment for fibromyalgia in ad ...

Natus Medical Incorporated has announced the global launch of the autoSCORE™ analysis tool, spreading the availability of the ...